文献速递创伤骨科骨质疏松与代谢性骨病

髋部新标准:通过住院患者静脉注射唑来膦酸改善骨质疏松症诊疗

A Hip New Standard: Improving Osteoporosis Care with Inpatient Administration of IV Zoledronate.
PubMed 文献 · J Bone Joint Surg Am · 2025-02-14

该质量改进项目在俄勒冈州波特兰市一家学术医疗中心开展,采用PDSA循环,为≥50岁低能量髋部骨折术后患者制定术后第2天静脉注射唑来膦酸并在住院期间正式诊断骨质疏松的流程。第二个PDSA循环后,唑来膦酸给药率从34.5%升至74.6%,骨质疏松诊断记录率从51.0%升至85.7%,住院时长无显著差异。

要点

  • 第二个PDSA循环后唑来膦酸给药率从34.5%(29/84)升至74.6%(53/71),p<0.001。
  • 第二个PDSA循环后骨质疏松诊断记录率从51.0%(53/104)升至85.7%(96/112),p<0.001。
  • 住院时长无显著差异;82例中1例因输注后急性期反应接受医学检查。

核心结论

  • 该举措有效改善了本机构老年髋部骨折患者的骨质疏松诊断与治疗。
  • 制定住院期间唑来膦酸给药方案是可靠地提供骨骼健康照护和二级骨折预防的方式,可在其他机构调整实施。

研究设计与样本

  • 质量改进项目,采用Plan-Do-Study-Act(PDSA)循环,在俄勒冈州波特兰市一家学术医疗中心开展,历时2.5年。
  • 制定方案:对因低能量髋部骨折接受手术的≥50岁住院患者,于术后第2天静脉给予唑来膦酸,并在住院期间正式诊断骨质疏松。
  • 方案以阶梯楔形方式在3个照护场景中引入。

主要发现

  • 第二个PDSA循环后,唑来膦酸给药率从34.5%(29/84)升至74.6%(53/71),p<0.001。
  • 第二个PDSA循环后,骨质疏松诊断记录率从51.0%(53/104)升至85.7%(96/112),p<0.001。
  • 住院时长无显著差异;82例中1例在给药后因输注后急性期反应接受医学检查。

关键数值与推荐

  • 纳入标准:年龄≥50岁、因低能量髋部骨折接受手术的住院患者。
  • 干预:术后第2天静脉给予唑来膦酸,并在住院期间正式诊断骨质疏松。
  • 结局指标:合格患者接受住院唑来膦酸给药的百分比和正式记录的骨质疏松诊断。
  • 平衡指标:给药后发热和住院时长(LOS)。

临床怎么用

  • 作者认为,制定住院期间唑来膦酸给药方案是可靠地提供骨骼健康照护和二级骨折预防的方式,可在其他机构调整实施。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteoporosis continues to be underdiagnosed and inadequately treated in older hip-fracture patients. Our aim was to improve the rate of osteoporosis treatment with IV bisphosphonate therapy in eligible patients admitted for hip-fracture surgery. METHODS: The present study was designed as a quality improvement initiative using Plan-Do-Study-Act (PDSA) cycles at an academic medical center in Portland, Oregon, over 2.5 years. A protocol was developed (1) to administer IV zoledronate on postoperative day 2 to inpatients aged ≥50 years who underwent surgery for a low-energy hip fracture and (2) to formally diagnose osteoporosis during admission. The protocol was introduced across 3 care settings in a stepped-wedge manner. Outcome measures were the percentage of inpatient zoledronate administered to eligible patients and formal documented diagnosis of osteoporosis. Balance measures included fever after administration and hospital length of stay (LOS). Measures were assessed through quarterly chart review and tracked via control charts. RESULTS: The rate of zoledronate administration significantly increased from 34.5% (29 of 84) to 74.6% (53 of 71) following the second PDSA cycle (p < 0.001). Documented osteoporosis diagnosis also significantly improved from 51.0% (53 of 104) to 85.7% (96 of 112) following the second PDSA cycle (p < 0.001). No significant differences were shown for hospital LOS, and 1 of 82 patients had medical work-up for post-infusion acute phase reaction after administration. CONCLUSIONS: This initiative was effective at improving osteoporosis diagnosis and treatment among older hip-fracture patients at our institution. Protocol development for administrating inpatient zoledronate after hip fracture is a reliable way to predictably offer bone health care and secondary-fracture prevention to hip-fracture patients and can be adapted and implemented at other institutions. LEVEL OF EVIDENCE: Diagnostic Level III . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Turner NM, Mayeda MS, De Lima B, et al. A Hip New Standard: Improving Osteoporosis Care with Inpatient Administration of IV Zoledronate. J Bone Joint Surg Am. 2025. PMID: 39951512. doi:10.2106/JBJS.24.00766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。